In summary, bronchiectasis complications include frequent exacerbations, cardiovascular events, hemoptysis, nontuberculous mycobacterial lung infections, respiratory failure, and even death.

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while ...

Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and hospitalization within 2 years of diagnosis, according to results published in BMC ...

Researchers also observed differences in 10-year mortality probability among those with suspected bronchiectasis in the PRISm group (0.07; 95% CI, –0.003 to 0.15) and in the obstructive ...

Non–cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory condition of the lungs associated with respiratory infections and daily cough and sputum. Non-cystic fibrosis bronchiectasis ...

FDA grants Priority Review for Insmed’s brensocatib for treatment of bronchiectasis with PDUFA target action date set for August 12, 2025. News release. Insmed. February 6, 2025.

Participants with suspected bronchiectasis had a 15% higher risk for 10-year mortality compared with those without airway thickening (difference in mortality probability, 0.15; 95% CI, 0.09 to 0.21).

Bronchiectasis, a condition defined by widened lung airways, cough and sputum production, and frequent infections, often presents along with chronic obstructive pulmonary disease (COPD). This ...

New drug shows promise for treating bronchiectasis Date: May 2, 2025 Source: University of Connecticut Summary: Results of a large, global clinical trial spanning five continents with over 1,700 ...

Change from baseline in the Quality of Life Bronchiectasis (QOL-B) Respiratory score: 2 points (P =.0594) and 3.8 points (P =.0004; nominal significant p-value).

Brensocatib is an oral, selective, competitive, and reversible inhibitor of DPP-1. 19 In the phase 2 WILLOW trial involving adults with bronchiectasis, treatment with a 10-mg or 25-mg dose of ...